Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

A. Berruti, R. Bitossi, G. Gorzegno, A. Bottini, D. Generali, M. Milani, D. Katsaros, I. A. Rigault De La Longrais, R. Bellino, M. Donadio, M. Ardine, O. Bertetto, S. Danese, M. G. Sarobba, A. Farris, V. Lorusso, L. Dogliotti

Research output: Contribution to journalArticle

Abstract

We investigated the activity and toxicity of a combination of vinorelbine (VNB), paclitaxel (PTX) and 5-fluorouracil (5-FU) continuous infusion administered as first-line chemotherapy in metastatic breast cancer patients pretreated with adjuvant anthracyclines. A total of 61 patients received a regimen consisting of VNB 25 mg m-2 on days 1 and 15, PTX 60 mg m-2 on days 1, 8 and 15 and continuous infusion of 5-FU at 200 mg m-2 every day. Cycles were repeated every 28 days. Disease response was evaluated by both RECIST and World Health Organization (WHO) criteria. Objective responses were recorded in 39 of 61 patients (64.0%) assessed by WHO and in 36 of 50 patients (72.0%) assessable by RECIST criteria. Complete remission occurred in 15 (24.6%) and 14 patients (28.0%), respectively. The median time to progression and overall survival of entire population was 10.6 and 27.3 months, respectively, and median duration of complete response was 14.8 months. The dose-limiting toxicity was myelosuppression (leucopenia grade 3/4 in 52.5% of patients). Grade 3/4 nonhaematologic toxicities included mucositis/diarrhoea in 13.1%, skin in 3.3% and cardiac in 1.6% of patients. Grade 2/3 neurotoxicity was observed in five patients (7.2%). The VNB, PTX and 5-FU continuous infusion combination regimen was active and manageable. Complete responses were frequent and durable.

Original languageEnglish
Pages (from-to)634-638
Number of pages5
JournalBritish Journal of Cancer
Volume92
Issue number4
DOIs
Publication statusPublished - Feb 28 2005

Fingerprint

Anthracyclines
Paclitaxel
Fluorouracil
Breast Neoplasms
Mucositis
vinorelbine
Leukopenia
Diarrhea
Drug Therapy
Skin
Survival
Population

Keywords

  • 5-fluorouracil
  • Breast cancer
  • Metastatic disease
  • Paclitaxel
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Berruti, A., Bitossi, R., Gorzegno, G., Bottini, A., Generali, D., Milani, M., ... Dogliotti, L. (2005). Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. British Journal of Cancer, 92(4), 634-638. https://doi.org/10.1038/sj.bjc.6602335

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. / Berruti, A.; Bitossi, R.; Gorzegno, G.; Bottini, A.; Generali, D.; Milani, M.; Katsaros, D.; Rigault De La Longrais, I. A.; Bellino, R.; Donadio, M.; Ardine, M.; Bertetto, O.; Danese, S.; Sarobba, M. G.; Farris, A.; Lorusso, V.; Dogliotti, L.

In: British Journal of Cancer, Vol. 92, No. 4, 28.02.2005, p. 634-638.

Research output: Contribution to journalArticle

Berruti, A, Bitossi, R, Gorzegno, G, Bottini, A, Generali, D, Milani, M, Katsaros, D, Rigault De La Longrais, IA, Bellino, R, Donadio, M, Ardine, M, Bertetto, O, Danese, S, Sarobba, MG, Farris, A, Lorusso, V & Dogliotti, L 2005, 'Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines', British Journal of Cancer, vol. 92, no. 4, pp. 634-638. https://doi.org/10.1038/sj.bjc.6602335
Berruti, A. ; Bitossi, R. ; Gorzegno, G. ; Bottini, A. ; Generali, D. ; Milani, M. ; Katsaros, D. ; Rigault De La Longrais, I. A. ; Bellino, R. ; Donadio, M. ; Ardine, M. ; Bertetto, O. ; Danese, S. ; Sarobba, M. G. ; Farris, A. ; Lorusso, V. ; Dogliotti, L. / Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. In: British Journal of Cancer. 2005 ; Vol. 92, No. 4. pp. 634-638.
@article{09052d8d2c5a42b3a04b37b4547d4cb6,
title = "Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines",
abstract = "We investigated the activity and toxicity of a combination of vinorelbine (VNB), paclitaxel (PTX) and 5-fluorouracil (5-FU) continuous infusion administered as first-line chemotherapy in metastatic breast cancer patients pretreated with adjuvant anthracyclines. A total of 61 patients received a regimen consisting of VNB 25 mg m-2 on days 1 and 15, PTX 60 mg m-2 on days 1, 8 and 15 and continuous infusion of 5-FU at 200 mg m-2 every day. Cycles were repeated every 28 days. Disease response was evaluated by both RECIST and World Health Organization (WHO) criteria. Objective responses were recorded in 39 of 61 patients (64.0{\%}) assessed by WHO and in 36 of 50 patients (72.0{\%}) assessable by RECIST criteria. Complete remission occurred in 15 (24.6{\%}) and 14 patients (28.0{\%}), respectively. The median time to progression and overall survival of entire population was 10.6 and 27.3 months, respectively, and median duration of complete response was 14.8 months. The dose-limiting toxicity was myelosuppression (leucopenia grade 3/4 in 52.5{\%} of patients). Grade 3/4 nonhaematologic toxicities included mucositis/diarrhoea in 13.1{\%}, skin in 3.3{\%} and cardiac in 1.6{\%} of patients. Grade 2/3 neurotoxicity was observed in five patients (7.2{\%}). The VNB, PTX and 5-FU continuous infusion combination regimen was active and manageable. Complete responses were frequent and durable.",
keywords = "5-fluorouracil, Breast cancer, Metastatic disease, Paclitaxel, Vinorelbine",
author = "A. Berruti and R. Bitossi and G. Gorzegno and A. Bottini and D. Generali and M. Milani and D. Katsaros and {Rigault De La Longrais}, {I. A.} and R. Bellino and M. Donadio and M. Ardine and O. Bertetto and S. Danese and Sarobba, {M. G.} and A. Farris and V. Lorusso and L. Dogliotti",
year = "2005",
month = "2",
day = "28",
doi = "10.1038/sj.bjc.6602335",
language = "English",
volume = "92",
pages = "634--638",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

AU - Berruti, A.

AU - Bitossi, R.

AU - Gorzegno, G.

AU - Bottini, A.

AU - Generali, D.

AU - Milani, M.

AU - Katsaros, D.

AU - Rigault De La Longrais, I. A.

AU - Bellino, R.

AU - Donadio, M.

AU - Ardine, M.

AU - Bertetto, O.

AU - Danese, S.

AU - Sarobba, M. G.

AU - Farris, A.

AU - Lorusso, V.

AU - Dogliotti, L.

PY - 2005/2/28

Y1 - 2005/2/28

N2 - We investigated the activity and toxicity of a combination of vinorelbine (VNB), paclitaxel (PTX) and 5-fluorouracil (5-FU) continuous infusion administered as first-line chemotherapy in metastatic breast cancer patients pretreated with adjuvant anthracyclines. A total of 61 patients received a regimen consisting of VNB 25 mg m-2 on days 1 and 15, PTX 60 mg m-2 on days 1, 8 and 15 and continuous infusion of 5-FU at 200 mg m-2 every day. Cycles were repeated every 28 days. Disease response was evaluated by both RECIST and World Health Organization (WHO) criteria. Objective responses were recorded in 39 of 61 patients (64.0%) assessed by WHO and in 36 of 50 patients (72.0%) assessable by RECIST criteria. Complete remission occurred in 15 (24.6%) and 14 patients (28.0%), respectively. The median time to progression and overall survival of entire population was 10.6 and 27.3 months, respectively, and median duration of complete response was 14.8 months. The dose-limiting toxicity was myelosuppression (leucopenia grade 3/4 in 52.5% of patients). Grade 3/4 nonhaematologic toxicities included mucositis/diarrhoea in 13.1%, skin in 3.3% and cardiac in 1.6% of patients. Grade 2/3 neurotoxicity was observed in five patients (7.2%). The VNB, PTX and 5-FU continuous infusion combination regimen was active and manageable. Complete responses were frequent and durable.

AB - We investigated the activity and toxicity of a combination of vinorelbine (VNB), paclitaxel (PTX) and 5-fluorouracil (5-FU) continuous infusion administered as first-line chemotherapy in metastatic breast cancer patients pretreated with adjuvant anthracyclines. A total of 61 patients received a regimen consisting of VNB 25 mg m-2 on days 1 and 15, PTX 60 mg m-2 on days 1, 8 and 15 and continuous infusion of 5-FU at 200 mg m-2 every day. Cycles were repeated every 28 days. Disease response was evaluated by both RECIST and World Health Organization (WHO) criteria. Objective responses were recorded in 39 of 61 patients (64.0%) assessed by WHO and in 36 of 50 patients (72.0%) assessable by RECIST criteria. Complete remission occurred in 15 (24.6%) and 14 patients (28.0%), respectively. The median time to progression and overall survival of entire population was 10.6 and 27.3 months, respectively, and median duration of complete response was 14.8 months. The dose-limiting toxicity was myelosuppression (leucopenia grade 3/4 in 52.5% of patients). Grade 3/4 nonhaematologic toxicities included mucositis/diarrhoea in 13.1%, skin in 3.3% and cardiac in 1.6% of patients. Grade 2/3 neurotoxicity was observed in five patients (7.2%). The VNB, PTX and 5-FU continuous infusion combination regimen was active and manageable. Complete responses were frequent and durable.

KW - 5-fluorouracil

KW - Breast cancer

KW - Metastatic disease

KW - Paclitaxel

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=20144379904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144379904&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602335

DO - 10.1038/sj.bjc.6602335

M3 - Article

C2 - 15668714

AN - SCOPUS:20144379904

VL - 92

SP - 634

EP - 638

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -